Faculty Opinions recommendation of Purinergic receptors in the endocrine and exocrine pancreas.

Pancreatic cells contain specialised stores for ATP. Purinergic receptors (P2 and P1) and ecto-nucleotidases are expressed in both endocrine and exocrine calls, as well as in stromal cells. The pancreas, especially the endocrine cells, were an early target for the actions of ATP. After the historical perspective of purinergic signalling in the pancreas, the focus of this review will be the physiological functions of purinergic signalling in the regulation of both endocrine and exocrine pancreas. Next, we will consider possible interaction between purinergic signalling and other regulatory systems and their relation to nutrient homeostasis and cell survival. The pancreas is an organ exhibiting several serious diseases – cystic fibrosis, pancreatitis, pancreatic cancer and diabetes – and some are associated with changes in life-style and are increasing in incidence. There is upcoming evidence for the role of purinergic signalling in the pathophysiology of the pancreas, and the new challenge is to understand how it is integrated with other pathological processes.

Download Full-text

Purinergic receptors in the endocrine and exocrine pancreas

Purinergic Signalling ◽

10.1007/s11302-007-9087-6 ◽

2007 ◽

Vol 4 (3) ◽

pp. 237-253 ◽

Cited By ~ 69

Author(s):

I. Novak

Keyword(s):

Exocrine Pancreas ◽

Purinergic Receptors

Download Full-text

MICROCHEMICAL ASSAYS OF GLUCOSE AND GLUCOSE-6-PHOSPHATE IN MAMMALIAN PANCREATIC β-CELLS

Acta Endocrinologica ◽

10.1530/acta.0.0590479 ◽

1968 ◽

Vol 59 (3) ◽

pp. 479-486 ◽

Cited By ~ 12

Author(s):

Lars-Ake Idahl ◽

Bo Hellman

Keyword(s):

Glucose Level ◽

Exocrine Pancreas ◽

The Other ◽

Wide Concentration Range ◽

Β Cells ◽

Pancreatic Β Cells ◽

Enzymatic Cycling ◽

Glucose Diffusion ◽

Significant Barrier ◽

The Brain

ABSTRACT The combination of enzymatic cycling and fluorometry was used for measuring glucose and glucose-6-phosphate in pancreatic β-cells from obese-hyperglycaemic mice. The glucose level of the β-cells corresponded to that of serum over a wide concentration range. In the exocrine pancreas, on the other hand, a significant barrier to glucose diffusion across the cell membranes was demonstrated. During 5 min of ischaemia, the glucose level remained practically unchanged in the β-cells while it increased in the liver and decreased in the brain. The observation that the pancreatic β-cells are characterized by a relatively low ratio of glucose-6-phosphate to glucose may be attributed to the presence of a specific glucose-6-phosphatase.

Download Full-text

Faculty Opinions recommendation of Maintained tubuloglomerular feedback responses during acute inhibition of P2 purinergic receptors in mice.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.7881956.13058059 ◽

2011 ◽

Author(s):

John Lorenz

Keyword(s):

Purinergic Receptors ◽

Tubuloglomerular Feedback ◽

P2 Purinergic Receptors ◽

Feedback Responses

Download Full-text

The Therapeutic Potential of Purinergic Receptors in Alzheimer’s Disease and Promising Therapeutic Modulators

Mini-Reviews in Medicinal Chemistry ◽

10.2174/1389557520999201209211610 ◽

2020 ◽

Vol 20 ◽

Author(s):

Lili Pan ◽

Yu Ma ◽

Yunchun Li ◽

Haoxing Wu ◽

Rui Huang ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Purinergic Receptors ◽

Therapeutic Potential ◽

Purinergic Signaling ◽

Memory Loss ◽

Related Research ◽

Central Nervous System Disorders ◽

G Protein Coupled

Abstract:: Recent studies have proven that the purinergic signaling pathway plays a key role in neurotransmission and neuromodulation, and is involved in various neurodegenerative diseases and psychiatric disorders. With the characterization of the subtypes of receptors in purinergic signaling, i.e. the P1 (adenosine), P2X (ion channel) and P2Y (G protein-coupled), more attentions were paid to the pathophysiology and therapeutic potential of purinergic signaling in central nervous system disorders. Alzheimer’s disease (AD) is a progressive and deadly neurodegenerative disease that is characterized by memory loss, cognitive impairment and dementia. However, as drug development aimed to prevent or control AD follows a series of failures in recent years, more researchers focused on the neuroprotection-related mechanisms such as purinergic signaling in AD patients to find a potential cure. This article reviews the recent discoveries of purinergic signaling in AD, summaries the potential agents as modulators for the receptors of purinergic signaling in AD related research and treatments. Thus, our paper provided an insight for purinergic signaling in the development of anti-AD therapies.

Download Full-text